Literature DB >> 22237486

Risk of erectile dysfunction and retrograde ejaculation associated with thulium laser vaporesection of the prostate for bladder outflow obstruction: a retrospective study.

Carol Ling Sze Yee1, Raj P Pal, Andrew Batchelder, Masood A Khan.   

Abstract

OBJECTIVE: The aim of this study was to determine the incidence of erectile dysfunction and retrograde ejaculation following thulium:yttrium-aluminium-garnet (Tm:YAG) laser prostate vaporesection (ThuVaRP). PATIENTS AND METHODS: Between January 2009 and June 2010, 113 consecutive patients underwent ThuVaRP for bladder outflow obstruction. Of these, 54 (48%) were included in the study as they were able to maintain an erection for sexual intercourse prior to undergoing ThuVaRP. All patients had benign pathology and had not undergone previous bladder neck surgery. The incidence of erectile dysfunction and retrograde ejaculation was reported at a mean follow-up period of 12 months post-operatively.
RESULTS: The mean patient age was 71 years (range 46-90). The mean follow-up period was 12 months (range 4-21). 11 (20%) patients experienced worsening erectile function with 3 (6%) noticing an improvement. A total of 30 patients (56%) experienced some degree of retrograde ejaculation. 4 patients (7%) noticed an improvement in their ejaculation. Retrograde ejaculation was more common in patients with an indwelling catheter in situ for refractory urinary retention (43 vs. 17%, p = 0.04) and in diabetic patients (27 vs. 4%, p = 0.03). There was an increased trend of erectile dysfunction in men aged ≥70 years, with hypertension and with hypercholesterolaemia, but this was not significant.
CONCLUSION: Our retrospective study has demonstrated that the overall risk of erectile dysfunction and retrograde ejaculation associated with ThuVaRP is 20 and 56%, respectively.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237486     DOI: 10.1159/000333046

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Impact of 120-W 2-μm continuous wave laser vapoenucleation of the prostate on sexual function.

Authors:  Yubin Wang; Jinkai Shao; Yongning Lu; Yongan Lü; Xiaodong Li
Journal:  Lasers Med Sci       Date:  2013-07-05       Impact factor: 3.161

Review 2.  Nomenclature in thulium laser treatment of benign prostatic hyperplasia: it's time to pull the rabbit out of the hat.

Authors:  Serena Maruccia; Irene Fulgheri; Emanuele Montanari; Stefano Casellato; Luca Boeri
Journal:  Lasers Med Sci       Date:  2021-01-03       Impact factor: 3.161

3.  Longitudinal changes in erectile function after thulium:YAG prostatectomy for the treatment of benign prostatic obstruction: a 1-year follow-up study.

Authors:  Jae Seung Chung; Sang Hyun Park; Cheol Kyu Oh; Seong Cheol Kim; Taek Sang Kim; Pil Moon Kang; Won Ik Seo; Wan Seok Kim; Jang Ho Yoon; Dong Ii Kang; Kweon Sik Min; Jae Ii Chung
Journal:  Lasers Med Sci       Date:  2017-07-06       Impact factor: 3.161

4.  Sexual outcome of patients undergoing thulium laser enucleation of the prostate for benign prostatic hyperplasia.

Authors:  Luca Carmignani; Giorgio Bozzini; Alberto Macchi; Serena Maruccia; Stefano Picozzi; Stefano Casellato
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

5.  Clinical Background of Patients with Sperm in Their Urinary Sediment.

Authors:  Masuomi Tomita; Eiji Kikuchi; Takahiro Maeda; Yusuke Kabeya; Takeshi Katsuki; Yoichi Oikawa; Kiyoe Kato; Masakazu Ohashi; So Nakamura; Mototsugu Oya; Akira Shimada
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

Review 6.  Assessment of Sexual Outcomes in Patients Undergoing Thulium Laser Prostate Surgery for Management of Benign Prostate Hyperplasia: A Systematic Review and Meta-analysis.

Authors:  Bibo Li; Lin Hao; Kun Pang; Guanghui Zang; Jian Wang; Chendi Yang; Jianjun Zhang; Longjun Cai; Xitao Wang; Conghui Han
Journal:  Sex Med       Date:  2022-01-16       Impact factor: 2.523

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.